Mark Weeks

Cooley advised Allay Therapeutics, a clinical-stage biotechnology company pioneering ultrasustained analgesic products to transform postsurgical pain management and recuperation, on its $57.5 million Series D financing.

Cooley advised NeuroPace (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, on its $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility.

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering.